Emerging trends in disturbed function of the pancreas and dyspepsia: an Indian perspective

Ramesh Roop Rai; Partha Pratim Bose

doi:10.18203/2349-3933.ijam20240682

Authors

Ramesh Roop Rai Rai Specialty Centre, Jaipur, Rajasthan, India
Partha Pratim Bose Peerless Hospitex Hospital and Research Center Limited, Kolkata, West Bengal, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20240682

Keywords:

EPI, Dyspepsia, Compliance, PERT, Pancreas

Abstract

Disturbed function of the pancreas, especially exocrine pancreatic insufficiency (EPI) results in inadequate synthesis or delivery of the pancreatic enzyme leading to maldigestion. Due to the lack of specific symptoms and overlapping manifestations of EPI, it often goes undiagnosed and untreated. Dyspepsia is another common condition characterized by upper gastrointestinal symptoms caused by a heterogeneous group of disorders. This consensus aims at providing a comprehensive overview of the diagnosis and management of disturbed function of the pancreas and dyspepsia. A total of 95 gastroenterologists participated in expert group meetings organized via virtual focus group discussions. Recent evidence elaborating various aspects like diagnosis and management of EPI and dyspepsia, including the use of pancreatic enzyme replacement therapy (PERT) and issues with compliance were discussed. The experts emphasized that clinical symptoms of maldigestion should not be ignored, and physicians should not wait to diagnose EPI until steatorrhea occurs. Fecal elastase (FE) test and imaging should be performed to confirm diagnosis. If EPI is diagnosed or the patient experiences weight loss or steatorrhea, PERT should be initiated while ensuring compliance. Reducing pill burden, active education, monitoring, and support from healthcare programs may help ensure compliance. EPI is also a cause of dyspepsia. Further, consuming lipid-rich foods worsens symptoms of dyspepsia. First-line treatment includes dietary changes and lifestyle modifications. Digestive enzyme supplements play a significant role in alleviating symptoms of indigestion. Routine enzyme supplementation is beneficial in managing dyspepsia caused by EPI, such as, in patients with EPI due to pancreatitis or diabetes.

Metrics

Metrics Loading ...

References

Brennan GT, Saif MW. Pancreatic enzyme replacement therapy: a concise review. JOP. 2019;20(5):121-5.

Ghodeif AO, Azer SA. Pancreatic insufficiency. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

Nieto JM, Bastidas A. Exocrine pancreatic insufficiency: a literature review. Gastroenterol Hepatol Open Access. 2016;4(2):00092.

Chaudhary A, Domínguez-Muñoz JE, Layer P, Lerch MM. Pancreatic exocrine insufficiency as a complication of gastrointestinal surgery and the impact of pancreatic enzyme replacement therapy. Dig Dis. 2020;38(1):53-68.

Ladabaum U, Chey WD. Uninvestigated dyspepsia. Curr Treat Options Gastroenterol. 2002;5(2):125-31.

Ford AC, Moayyedi P. Managing dyspepsia. Curr Gastroenterol Rep. 2009;11(4):288-94.

Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-39.

Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018;34(5):349-354.

Benjamin O, Lappin SL. Chronic pancreatitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

Rosendahl J, Bödeker H, Mössner J, Teich N. Hereditary chronic pancreatitis. Orphanet J Rare Dis. 2007;2(1):1.

Perbtani Y, Forsmark CE. Update on the diagnosis and management of exocrine pancreatic insufficiency. F1000Res. 2019;8.

Talukdar R, Reddy DN. Pancreatic exocrine insufficiency in type 1 and 2 diabetes: Therapeutic implications. J Assoc Physicians India. 2017;65(9):64-70.

Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19(42):7258-66.

Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract. 2018;72(2):e13066.

Nikfarjam M, Wilson JS, Smith RC. Diagnosis and management of pancreatic exocrine insufficiency. Med J Aust. 2017;207(4):161-5.

Berry AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract. 2014;29(3):312-21.

De la Iglesia-García D, Huang W, Szatmary P, Baston-Rey I, Gonzalez-Lopez J, Prada-Ramallal G, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2017;66(8):1354-5.

Toskes PP, Secci A, Thieroff-Ekerdt R, ZENPEP Study Group. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. Pancreas. 2011;40(3):376-82.

Kuhn RJ, Gelrud A, Munck A, Caras S. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. Advances in therapy. 2010;27:895-916.

Barkin JA, Westermann A, Hoos W, Moravek C, Matrisian L, Wang H, et al. Frequency of appropriate use of pancreatic enzyme replacement therapy and symptomatic response in pancreatic cancer patients. Pancreas. 2019;48(6):780-6.

Leung G, Buscaglia JM. Pancreatic enzyme replacement therapy in post-Whipple patients: optimizing the dose and maximizing compliance. Clin Gastroenterol Hepatol. 2020;18(4):789-91.

Khandelwal N, Wang S, Johns B, Vora J, Castelli-Haley J, Singh VK. Economic impact of treatment adherence in exocrine pancreatic insufficiency (EPI) patients treated with pancreatic enzyme replacement therapy (PERT). Value in Health. 2018;2:S85-6.

Kamat N, Pai G, Mallayasamy SR, Kamath A. Direct costs for nonsurgical management of Chronic Pancreatitis in a tertiary care teaching hospital. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):315-20.

Kumar A, Pate J, Sawant P. Epidemiology of functional dyspepsia. J Assoc Physicians India. 2012;60:9-12.

Harmon RC, Peura DA. Evaluation and management of dyspepsia. Therap Adv Gastroenterol. 2010;3(2):87-98.

Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet. 2020;396(10263):1689-702.

Schachter H. Indigestion and Heartburn. In: Walker HK, Hall WS, Hurst JW, eds. Clinical Methods, The History, Physical, and Laboratory Examination, 3rd ed. Boston, Butterworths. 1990.

Ghoshal UC, Singh R, Chang FY, Hou X, Wong BC, Kachintorn U. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil. 2011;17(3):235-44.

Khodarahmi M, Azadbakht L. Dietary fat intake and functional dyspepsia. Adv Biomed Res. 2016;5:76.

Fried M, Feinle C. The role of fat and cholecystokinin in functional dyspepsia. Gut. 2002;51(1):i54-7.

Bonetto S, Gruden G, Beccuti G, Ferro A, Saracco GM, Pellicano R. Management of dyspepsia and gastroparesis in patients with diabetes. A clinical point of view in the year 2021. J Clin Med. 2021;10(6):1313.

Suzuki H. Recent advances in the definition and management of functional dyspepsia. Keio J Med. 2021;70(1):7-18.

Domínguez‐Muñoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. HPB (Oxford). 2009;11:3-6.

Francis P, Zavala SR. Functional Dyspepsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.

Swami OC, Shah NJ. Functional dyspepsia and the role of digestive enzymes supplement in its therapy. Int J Basic Clin Pharmacol. 2017;6(5):1035-41.

Shrikhande SV, Prasad VM, Domínguez-Muñoz JE, Weigl KE, Sarda KD. In vitro comparison of pancreatic enzyme preparations available in the Indian market. Drug Des Devel Ther. 2021;15:3835-43.

Ianiro G, Pecere S, Giorgio V, Gasbarrini A, Cammarota G. Digestive enzyme supplementation in gastrointestinal diseases. Curr Drug Metab. 2016;17(2):187-93.

Majeed M, Majeed S, Nagabhushanam K, Arumugam S, Pande A, Paschapur M, et al. Evaluation of the safety and efficacy of a multienzyme complex in patients with functional dyspepsia: a randomized, double-blind, placebo-controlled study. J Med Food. 2018;21(11):1120-8.